THOROFARE, N.J., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "Akers Biosciences), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announced the pricing of an underwritten public offering of 2,727,000 shares (the "Shares") of common stock at a public offering price of $5.50 per share. The shares will begin trading on The NASDAQ Capital Market on January 23, 2014 at approximately 2:10 PM EST under the symbol "AKER." The Company expects to receive approximately $15,000,000 in gross proceeds, before underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the representative of the underwriters a 45-day option to purchase up to 409,050 additional shares of common stock.
Help employers find you! Check out all the jobs and post your resume.
